Biomarin Pharmaceutical Inc (OQ:BMRN)

Feb 22, 2024 03:03 pm ET
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earnings per Share of $2.08 (+36% Y/Y)
Feb 08, 2024 07:00 am ET
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
SAN RAFAEL, Calif., Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m. ET to discuss fourth quarter and full-year 2023 financial results and provide a general business update.
Feb 06, 2024 07:30 am ET
Jan 03, 2024 07:00 am ET
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
SAN RAFAEL, Calif., Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 42nd Annual J.P. Morgan Conference on Monday January 8, 2024, at 10:30 am PT / 1:30 pm ET, in San Francisco, California. 
Dec 20, 2023 03:05 pm ET
BioMarin Announces Governance Enhancements and Value Creation Initiatives
Board Approves Appointment of Three New Independent Directors
Nov 28, 2023 07:30 am ET
Nov 01, 2023 04:05 pm ET
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
• Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO® and ROCTAVIAN® Net Product Revenue Guidance Adjusted for Full-year 2023
Nov 01, 2023 04:02 pm ET
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
Mr. Hardy Brings More than 30 Years of Industry Experience, Most Recently as CEO of Genentech
Oct 20, 2023 04:05 pm ET
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
Expanded Indication in the U.S. Now Includes Children of all ages with Achondroplasia
Oct 17, 2023 08:30 am ET
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
SAN RAFAEL, Calif., Oct. 17, 2023  /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, November 1, at 4:30 p.m. ET to discuss third-quarter 2023 financial results and provide a general business update.
Sep 11, 2023 08:30 am ET
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
Live Audio Webcast to Begin at 8:00 a.m. Eastern Time
Aug 09, 2023 06:14 pm ET
Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements
Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against each of these companies. To receive a pro-rata share of the settlement proceeds, members of the class must...
Jul 31, 2023 04:03 pm ET
BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 GuidancePivotal Program with VOXZOGO in New, Potential Second Indication, Hypochondroplasia, to Begin in the Fourth Quarter of 2023U.S. Approval of ROCTAVIAN™ Received in the Second Quarter and Commercial Launch Underway; Commercial Launch in Europe Making ProgressFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)
Jul 12, 2023 09:27 am ET
BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET
SAN RAFAEL, Calif., July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, July 31, at 4:30 p.m. ET to discuss second-quarter 2023 financial results and provide a general business update.
Jun 30, 2023 09:31 am ET
Thinking about trading options or stock in Alphabet Inc, Ford Motor Co, PacWest Bancorp, SoFi Technologies, or Biomarin Pharmaceutical?
NEW YORK, June 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOOGL, F, PACW, SOFI, and BMRN.
Jun 29, 2023 02:34 pm ET
Jun 22, 2023 08:00 am ET
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (IST
New Data to be Presented for ROCTAVIAN from Phase 3 GENEr8-1 Study, Including Data on the Impact of ROCTAVIAN on Quality of Life and Musculoskeletal Health for Adults with Severe Hemophilia A
May 04, 2023 04:01 pm ET
BioMarin to Participate in Bank of America 2023 Health Care Conference
SAN RAFAEL, Calif., May 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will present at the Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:40pm PT, in Las Vegas, NV. 
Apr 26, 2023 04:03 pm ET
BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 GuidanceFull-year 2023 Top-line and Bottom-line Financial Guidance Reaffirmed; ROCTAVIAN™ Net Product Revenue Guidance Adjusted for Full-year 2023In Germany, Growing Pipeline of People with Severe Hemophilia A Getting Tested for ROCTAVIAN Treatment Eligibility; ROCTAVIAN U.S. Launch Preparations Underway Ahead of June 30 Prescription Drug User Fee Act (PDUFA) Target Action DateFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)
Apr 13, 2023 08:30 am ET
BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET
SAN RAFAEL, Calif., April 13, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 26, at 4:30 p.m. ET to discuss first-quarter 2023 financial results and provide a general business update.
Mar 14, 2023 08:00 am ET
BioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Achondr
New Analyses from Phase 2 and Phase 3 Extension Studies Continue to Demonstrate Sustained Improvement in Growth with no Change in Safety Profile
Feb 27, 2023 03:03 pm ET
BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 BillionIn 2023, More than 15% Growth in Total Revenues and Approximately 30% Growth in Net Income Expected Based on Mid-point of Today's Full-year Guidance; VOXZOGO Revenues Expected to More than DoubleROCTAVIAN European Commercial Launch and U.S. Launch Preparations Both Underway; 3-year Analysis from Phase 3 ROCTAVIAN Study in Adults with Severe Hemophilia A Recently Submitted to the FDAFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)
Feb 14, 2023 07:30 am ET
BioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023
SAN RAFAEL, Calif., Feb. 14, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer and Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will participate virtually in the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023, at 11:20 a.m. ET.
Feb 07, 2023 07:00 am ET
BioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET
SAN RAFAEL, Calif., Feb. 7, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 27, at 4:30 p.m. ET to discuss fourth quarter and full-year 2022 financial results and provide a general business update.
Jan 08, 2023 10:00 am ET
Jan 05, 2023 08:41 am ET
Thinking about trading options or stock in Biomarin Pharmaceutical, Docusign, Apple, MicroStrategy, or Allstate Corp?
NEW YORK, Jan. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMRN, DOCU, AAPL, MSTR, and ALL.
Jan 04, 2023 07:30 am ET
BioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA
SAN RAFAEL, Calif., Jan. 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at  the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 10:30 am PT / 1:30 pm ET, in San Francisco, California. To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following the event. 
Jan 03, 2023 03:05 pm ET
European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
BioMarin Submits Supplemental New Drug Application to U.S. Food and Drug Administration to Expand Label to Treat Children with Achondroplasia Under the Age of 5
Nov 23, 2022 07:29 am ET
BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA)
Nov 03, 2022 08:30 am ET
BioMarin to Participate in Two Upcoming Investor Conferences
Credit Suisse 31st Annual Healthcare Conference 2022: November 8th, 8:35amPT/11:35amET, in Rancho Palos Verdes, CA13th Annual Jefferies Global Healthcare Conference 2022: November 16th, 8:35amGMT, in London, EnglandSAN RAFAEL, Calif., Nov. 3, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at two upcoming investor conferences. To access the live webcasts, please visit: https://investors.biomarin.com/.  An archived version of the presentations will also be available through the Company's website for a limited time following the con
Oct 26, 2022 04:03 pm ET
BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
VOXZOGO® $48 Million Contribution in the Quarter Results in BioMarin Raising Full-year 2022 VOXZOGO Net Product Revenue Guidance to Between $140 Million and $170 MillionU.S. Biologics Application for ROCTAVIAN™ Accepted by U.S. Food and Drug Administration (FDA); Prescription Drug User Fee Act (PDUFA) Target Action Date is March 31, 2023; Commercial Launch of ROCTAVIAN Underway in the European Union (EU) Following August 24, 2022 ApprovalFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)
Oct 12, 2022 04:05 pm ET
Oct 06, 2022 07:00 pm ET
BioMarin Simplifies Organizational Structure to Increase Efficiency
SAN RAFAEL, Calif., Oct. 6, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus investments that advance its R&D pipeline, maximize recent commercial launch success, prepare for a potential launch of ROCTAVIAN™ (valoctocogene roxaparvovec) in the U.S., and drive core infrastructure optimization. This redesign simplifies the organization, creates efficiencies, reduces the average management layers across the organization and prioritizes and heightens the capabilities required to achieve critical business
Oct 04, 2022 08:30 am ET
BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET
SAN RAFAEL, Calif., Oct. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 26th, at 4:30 p.m. ET to discuss third quarter 2022 financial results and provide a general business update.
Sep 29, 2022 04:04 pm ET
Sep 15, 2022 08:31 am ET
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report
Institute for Clinical and Economic Review (ICER) Base-Case Model Report Results in $4 Million Savings Versus Emicizumab Prophylaxis Per Patient Over a Lifetime
Sep 09, 2022 10:50 pm ET
BIOMARIN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
NEW ORLEANS, Sept. 9, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). 
Aug 26, 2022 10:50 pm ET
BIOMARIN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
NEW ORLEANS, Aug. 26, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).
Aug 24, 2022 04:36 pm ET
Aug 12, 2022 11:01 pm ET
BIOMARIN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
NEW ORLEANS, Aug. 12, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).  
Aug 03, 2022 04:03 pm ET
BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance
VOXZOGO™ $34 Million Contribution Drives Total Revenues of $534 Million in the Quarter; Total Revenues Grew 13% Year-Over-Year, Excluding KuvanBioMarin Expects that ROCTAVIAN™ (valoctocogene roxaparvovec) for the Treatment of Severe Hemophilia A Will Be Approved in Europe in the Third Quarter; Re-Submission of Biologics License Application (BLA) in the U.S. Planned for September 2022Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
Jul 20, 2022 01:49 pm ET
BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET
SAN RAFAEL, Calif., July 20, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 3rd, at 4:30 p.m. ET to discuss second quarter 2022 financial results and provide a general business update.
Jul 11, 2022 08:31 am ET
BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Includin
Commitment to Advancing Care for People with Hemophilia A Demonstrated with Largest and Longest, Ongoing Clinical Development Program for any Gene Therapy in Hemophilia A
May 31, 2022 08:31 am ET
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
95% Reduction in Mean Annualized Bleed Rate (ABR) and 96% Reduction in Mean Annualized Factor VIII Usage from Baseline Through Year 6 in 6e13 vg/kg Dose Cohort91% Reduction in Mean ABR and 93% Reduction in Mean Annualized Factor VIII Usage from Baseline Through Year 5 in 4e13 vg/kg Dose CohortData from Phase 1/2 Study to be Shared in Oral Presentation at Upcoming International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress (July 9-13)BLA Resubmission Now Expected by End of September to Provide Additional Information Requested by FDAMAA Under Review by the European Medicines Agenc
May 05, 2022 04:04 pm ET
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
Humaira Serajuddin Named to Newly Created Role of Senior Vice President, Chief Marketing Officer
May 05, 2022 08:29 am ET
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five
Ongoing Clinical Development Program Represents Largest and Longest Development Program for any Gene Therapy in Hemophilia A, Demonstrates Commitment to Advancing Care for People with Hemophilia A
May 04, 2022 09:00 am ET
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
SAN RAFAEL, Calif., May 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the BofA Securities Healthcare Conference on May 12 at 8:40am PT/11:40am ET in Las Vegas. To access the live webcast, please visit the BioMarin website, https://investors.biomarin.com/.
Apr 27, 2022 04:02 pm ET
BioMarin Announces Record Revenues in First Quarter 2022
BioMarin Reports Record First Quarter Total Revenues of $519 Million Driven by a $20 Million VOXZOGO Contribution; Total Revenues Grew 11% Year-over-Year, Excluding KuvanFull-year 2022 Financial Guidance for Voxzogo Net Product Revenues Increased to between $100 Million to $125 Million; Remaining Guidance ReaffirmedValoctocogene Roxaparvovec for the Treatment of Severe Hemophilia A Under Review in Europe with Committee for Medicinal Products for Human Use (CHMP) Opinion Anticipated Mid-year 2022; Re-submission of the Biologics License Application (BLA) in the U.S. Planned in JuneGenomic Anal
Apr 13, 2022 03:31 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of BioMarin Pharmaceutical Inc. (NASDAQGS: BMRN), On24, Inc. (NYSE: ONTF), Silverback Therapeutics, Inc. (NASDAQ: SBTX), and Selectquote, Inc. (NYSE: S
BioMarin Pharmaceutical Inc. (NASDAQGS: BMRN) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of BioMarin alleging that Defendants made false and/or misleading statements and/or failed to...
Apr 13, 2022 09:00 am ET
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET
SAN RAFAEL, Calif., April 13, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 27th, at 4:30 p.m. ET to discuss first quarter 2022 financial results and provide a general business update.
Mar 04, 2022 09:00 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Ardelyx, BioMarin, Chegg, and ChemoCentryx on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Ardelyx, Inc. (NASDAQ: ARDX), BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN), Chegg, Inc. (NYSE: CHGG), and...
Feb 23, 2022 03:03 pm ET
Feb 17, 2022 03:05 pm ET
BioMarin Provides Updates on Progress in Gene Therapy Programs
SAN RAFAEL, Calif., Feb. 17, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on its investigational gene therapy programs in clinical development.  In February 2022, the Company received additional requests from the Food and Drug Administration (FDA) for information needed to resolve the clinical hold of the PHEARLESS Phase 1/2 study of BMN 307 issued in September 2021.  BMN 307 is an AAV5-human phenylalanine hydroxylase (hPAH) gene therapy being studied in adults with phenylketonuria (PKU). The FDA has requested data from additional non-clinical studies to
Feb 16, 2022 03:00 pm ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
SAN RAFAEL, Calif., Feb. 16, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.  An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Feb 11, 2022 09:06 pm ET
BIOMARIN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
NEW ORLEANS, Feb. 11, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).  
Feb 10, 2022 08:00 am ET
BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET
SAN RAFAEL, Calif., Feb. 10, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 23rd, at 4:30 p.m. ET to discuss fourth quarter and full year 2021 financial results and provide a general business update.
Feb 09, 2022 07:31 am ET
BioMarin Sells Priority Review Voucher for $110 Million
SAN RAFAEL, Calif., Feb. 9, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in November 2021 for a lump sum payment of $110,000,000. The Company received the voucher under a Food and Drug Administration (FDA) program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of VOXZOGO™ (vosoritide) for Injection, indicated to i
Feb 04, 2022 10:15 am ET
BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and All
SAN RAFAEL, Calif., Feb. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety update of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).  This is the largest global Phase 3 study to date for any gene therapy in hemophilia with 134 participants. 
Feb 03, 2022 06:24 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
Wilmington, Delaware--(Newsfile Corp. - February 3, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) on behalf of stockholders.
Feb 02, 2022 03:04 pm ET
BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-
SAN RAFAEL, Calif., Feb. 2, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company will be presenting data in several presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4.  Notably, there will be an oral presentation of data from the two-year analysis of an ongoing global Phase 3 study, GENEr8-1, the largest Phase 3 gene therapy study in severe hemophili
Jan 28, 2022 08:50 pm ET
BIOMARIN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
NEW ORLEANS, Jan. 28, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).
Jan 24, 2022 05:10 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. (“BioMarin”) (NasdaqGS: BMRN) on behalf of long-term stockholders. On October 25, 2021, a class action complaint was filed...
Jan 14, 2022 10:16 pm ET
BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
NEW ORLEANS, Jan. 14, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).  
Jan 10, 2022 08:31 am ET
Thinking about trading options or stock in BioMarin Pharmaceutical, Dell Technologies, Apple, ConocoPhillips, or Kroger?
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMRN, DELL, AAPL, COP, and KR.
Jan 09, 2022 02:13 pm ET
BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficac
SAN RAFAEL, Calif., Jan. 9, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A.  This is the largest global Phase 3 study to date for any gene therapy in hemophilia, with 134 participants.
Jan 04, 2022 05:00 am ET
BioMarin to Participate in Two Virtual Investor Conferences in January
BioMarin to Present at Two Investor Conferences in January 2022SAN RAFAEL, Calif., Jan. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two virtual conferences in January. To access the live webcasts, please visit: https://investors.biomarin.com/.  An archived version of the presentations will also be available through the Company's website for a limited time following the conference.
Dec 29, 2021 09:00 pm ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. is Investigating BioMarin Pharmaceuticals on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioMarin Pharmaceuticals (NASDAQ: BMRN) on behalf of long-term stockholders following a class action complaint that was...
Dec 23, 2021 01:00 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of Amarin Corporation plc (NASDAQGM: AMRN), BioMarin Pharmaceutical Inc. (NASDAQGS: BMRN), InnovAge Holding Inc. (NASDAQGS: INNV), and Lightning eMotor
Amarin Corporation plc (NASDAQGM: AMRN) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against Amarin alleging that Defendants made false and misleading statements and/or failed to disclose that: (i) there was an...
Dec 22, 2021 07:42 pm ET
Dec 22, 2021 04:00 pm ET
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. (BMRN) Investors of Class Action
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Dec 21, 2021 09:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period"), seeking to re
Dec 21, 2021 01:16 pm ET
BMRN FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December...
Dec 21, 2021 10:43 am ET
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in BioMarin Pharmaceutical Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, Dec. 21, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 20, 2021 10:04 am ET
BMRN & RECAF – Upcoming Lead Deadlines: Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 19, 2021 09:36 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline – BMRN
Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers.   The class action, filed in the United States District Court for the...
Dec 16, 2021 07:30 pm ET
ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December...
Dec 16, 2021 03:05 pm ET
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
SAN RAFAEL, Calif. and SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing novel treatments for unmet medical needs, today announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus (AAV) gene therapies to treat genetic cardiovascular diseases.
Dec 15, 2021 06:20 pm ET
Dec 15, 2021 03:05 pm ET
BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors
SAN RAFAEL, Calif., Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors effective January 1, 2022.   
Dec 14, 2021 09:00 pm ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States...
Dec 14, 2021 10:00 am ET
AMRN, BMRN & RECAF – Upcoming Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 09, 2021 09:00 pm ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States...
Dec 07, 2021 05:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline – BMRN
Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers. The class action, filed in the United States District Court for the...
Dec 07, 2021 12:18 pm ET
ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December...
Dec 06, 2021 03:44 pm ET
Dec 04, 2021 05:00 am ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States...
Dec 04, 2021 05:00 am ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States...
Dec 02, 2021 10:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period"), seeking to rec
Nov 30, 2021 06:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline – BMRN
Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers.   The class action, filed in the United States District Court for the...
Nov 30, 2021 10:00 am ET
AMRN, BMRN & RECAF – Upcoming Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Nov 30, 2021 07:45 am ET
BioMarin to Hold Virtual R&D Day at 11:00am ET Today
SAN RAFAEL, Calif., Nov. 30, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host a virtual R&D Day beginning at 8:00am PT/11:00am ET today, Tuesday, November 30, 2021.  BioMarin management and external experts will provide an update to the investment community on the Company's earlier-stage development portfolio, which is focused on translating genetic discoveries into transformative medicines.
Nov 29, 2021 08:23 pm ET
Nov 29, 2021 07:30 am ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
SAN RAFAEL, Calif., Nov. 29, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual investor conferences.  An audio webcast of the presentations will be available live.  You can access the webcasts at: https://investors.biomarin.com/.  An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Nov 29, 2021 05:00 am ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States...
Nov 29, 2021 05:00 am ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States...
Nov 28, 2021 11:00 am ET
ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December...
Nov 24, 2021 02:16 pm ET
Levi & Korsinsky, LLP, Researching Possible Securities Law Violations - BioMarin Pharmaceutical Inc. - BMRN
NEW YORK, Nov. 24, 2021 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:
Nov 24, 2021 10:02 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the F
LOS ANGELES, Nov. 24, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 23, 2021 03:24 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ:
Nov 22, 2021 10:00 pm ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States...
Nov 22, 2021 06:03 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ:
Nov 19, 2021 06:34 pm ET
INVESTOR REMINDER: BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION DEADLINE- Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securiti
NEW YORK, Nov. 19, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than December 21, 2021 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) from January 13, 2020 through September 3, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Sec
Nov 19, 2021 10:00 am ET
AMRN, BMRN & RECAF – Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Nov 19, 2021 09:42 am ET
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated to increase linear growth in pediatric patients with achondroplasia five years of age and older with open epiphyses (growth plates).  This indication is approved under accelerated approval based on an improvement in annualized growth velocity (AGV). Continued approval for this indication may be contingent upon verification and description of clinical ben
Nov 16, 2021 09:00 pm ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States...
Nov 15, 2021 07:30 am ET
Entos and BioMarin Enter into Agreement for Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform
-- Entos will apply the Fusogenix platform to formulate BioMarin product candidates aimed at the treatment of genetic diseases
Nov 15, 2021 07:30 am ET
Entos and BioMarin Enter into Agreement for Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform
-- Entos will apply the Fusogenix platform to formulate BioMarin product candidates aimed at the treatment of genetic diseases
Nov 13, 2021 12:15 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December...
Nov 12, 2021 10:00 am ET
AMRN, BMRN & RECAF – Class Action Alerts: Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Nov 11, 2021 10:33 am ET
BioMarin Pharmaceutical Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the N
NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a federal securities class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) in the United States District Court for the Northern District of California, on behalf of a class consisting of all persons and entities that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period").
Nov 10, 2021 09:00 pm ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioMarin securities between January 1, 2020 and September 3, 2021, both dates inclusive (the “Class Period”). Investors have until December 21, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Nov 10, 2021 01:15 pm ET
INVESTOR REMINDER: BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION DEADLINE- Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securiti
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than December 21, 2021 in a securities class action lawsuit that has been filed on behalf of investors...
Nov 09, 2021 03:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline – BMRN
Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers.   The class action, filed in the United States District Court for the...
Nov 09, 2021 11:00 am ET
BIOMARIN DEADLINE ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioMarin To Contact Him Directly To Discus
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and reminds investors of the December 22, 2021 deadline to seek the...
Nov 06, 2021 11:14 am ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December 22, 2021 lead plaintiff deadline.
Nov 04, 2021 02:21 am ET
BIOMARIN PHARMACEUTICAL INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the N
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) in the United States District Court for the Northern District of California, on behalf of a class consisting of all persons and entities that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period").
Nov 03, 2021 06:45 pm ET
BMRN INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December...
Nov 03, 2021 11:00 am ET
BMRN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: December 21, 2021
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers, on behalf of...
Nov 02, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against D-Market, Gaotu, Amarin, and BioMarin and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of D-Market Electronic Services & Trading (NASDAQ: HEPS), Gaotu Techedu Inc. (NYSE:...
Nov 01, 2021 08:29 am ET
SHAREHOLDER ALERT: Robbins LLP Announces that BioMarin Pharmaceutical Inc. (BMRN) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, for violations of the Securities Exchange Act of 1934. BioMa
Oct 30, 2021 10:03 am ET
ALERT: BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – BMRN
Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”) have until December 21, 2021 to seek appointment as lead plaintiff in Berlinger v
Oct 28, 2021 06:52 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action – BMRN
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021,...
Oct 28, 2021 01:10 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th
LOS ANGELES, Oct. 28, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Oct 28, 2021 10:00 am ET
BMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: December 21, 2021
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers, on behalf of...
Oct 28, 2021 08:32 am ET
BioMarin Pharmaceutical Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the N
NEW YORK, Oct. 28, 2021 /PRNewswire/ -- October 28, 2021 - Wolf Haldenstein Adler Freeman & Herz LLP  announces that a federal securities class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) in the United States District Court for the Northern District of California, on behalf of a class consisting of all persons and entities that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period").
Oct 27, 2021 09:00 pm ET
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioMarin securities between January 1, 2020 and September 3, 2021, both dates inclusive (the “Class Period”). Investors have until December 21, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Oct 27, 2021 05:31 pm ET
BIOMARIN PHARMACEUTICAL INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the N
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) in the United States District Court for the...
Oct 27, 2021 04:05 pm ET
BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
SAN RAFAEL, Calif., Oct. 27, 2021 /PRNewswire/ -- 
Oct 27, 2021 09:06 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ:
Oct 26, 2021 08:04 pm ET
BMRN DEADLINE: BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, Oct. 26, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, inclusive (the "Class Period") have until December 21, 2021 to seek appointment as lead plaintiff in the BioMarin class action lawsuit.  Commenced on October 22, 2021 in the Northern District of California, the BioMarin class action lawsuit (Berlinger v. BioMarin Pharmaceutical Inc., No. 21-cv-08254) charges BioMarin as well as certain of its top executives with violations of the Secur
Oct 26, 2021 03:50 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ:
Oct 26, 2021 12:38 pm ET
BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”) have until December 21, 2021 to seek appointment as lead plaintiff in Berlinger v
Oct 26, 2021 10:00 am ET
BMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: December 21, 2021
NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin between January 13, 2020 and September 3, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/bmrn.
Oct 25, 2021 08:33 pm ET
/C O R R E C T I O N -- Pomerantz LLP/
In the news release, Pomerantz Law Firm Announces the Filing of a Class Action Against BioMarin Pharmaceutical Inc. and Certain Officers - BMRN, issued 23-Oct-2021 by Pomerantz LLP over PR Newswire, we are advised by the company that the Lead Plaintiff Deadline date has been updated to December 22, 2021. The complete, corrected release follows:
Oct 25, 2021 06:45 pm ET
BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceutical Inc.
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) from January 13, 2020 through September 3, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Act of 1934.
Oct 25, 2021 06:09 pm ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 21, 2021.
Oct 25, 2021 03:48 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceutical Inc. (BMRN)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States District Court for the Northern District of California on behalf...
Oct 25, 2021 08:30 am ET
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
SAN RAFAEL, Calif., Oct. 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual investor conferences. An audio webcast of the presentations will be available live. You can access the webcasts at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Oct 23, 2021 12:00 am ET
Pomerantz Law Firm Announces the Filing of a Class Action Against BioMarin Pharmaceutical Inc. and Certain Officers - BMRN
NEW YORK, Oct. 23, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period"), seeking to r
Oct 12, 2021 08:30 am ET
BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET
SAN RAFAEL, Calif., Oct. 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 27, at 4:30 p.m. ET to discuss third quarter 2021 financial results and provide a general business update.
Oct 04, 2021 08:31 am ET
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations
SAN RAFAEL, Calif., Oct. 4, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans Harold S. Bernstein, M.D., Ph.D. as Senior Vice President, Chief Medical Officer and Head of Clinical Development and Ganesh Vedantham, as Senior Vice President, Technical Development filling two key strategic roles. 
Sep 20, 2021 12:48 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 09, 2021 09:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN
NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 06, 2021 02:00 am ET
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
SAN RAFAEL, Calif., Sept. 6, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study.  The Phearless study is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy, in adults with phenylketonuria (PKU).  The FDA's clinical hold was based on interim safety findings from a pre-clinical, non-GLP pharmacology study.  
Aug 27, 2021 09:01 am ET
European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
SAN RAFAEL, Calif., Aug. 27, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO® (vosoritide), a once daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.  Voxzogo is the first medicine to be approved to treat children with achondroplasia in Europe.  Voxzogo, a modified C-type natriuretic peptide (CNP), directly targets the underlying pathophysiology of achondroplasia
Aug 25, 2021 08:30 am ET
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
SAN RAFAEL, Calif., Aug. 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences. An audio webcast of the presentations will be available live. You can access the webcasts at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Jul 28, 2021 04:03 pm ET
Jul 21, 2021 10:01 am ET
BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Rox
SAN RAFAEL, Calif., July 21, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from its open-label Phase 1/2 study during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.   
Jul 19, 2021 11:00 am ET
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on
SAN RAFAEL, Calif., July 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its positive pivotal study, GENEr8-1, during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.  The pivotal study demonstrated superiority to Factor VIII prophylaxis in key clinical efficacy endpoints.  With 134 participants, this is the largest global Phase 3 study to date for gene therapy in hem
Jul 15, 2021 08:31 am ET
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
SAN RAFAEL, Calif., July 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A.  With today's validation the MAA review can now commence.  A CHMP opinion is anticipated in the first half of 2022.
Jul 14, 2021 08:30 am ET
BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET
SAN RAFAEL, Calif., July 14, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, July 28, at 4:30 p.m. ET to discuss second quarter 2021 financial results and provide a general business update.
Jul 02, 2021 09:05 am ET
BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
SAN RAFAEL, Calif., July 2, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress being held July 17-21, 2021. Notably, these presentations will include highlights from the Phase 3 GENEr8-1 trial, the largest gene therapy trial in Hemophilia A, and five years of clinical follow-up from the Phase 1/2 st
Jun 28, 2021 08:31 am ET
BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
SAN RAFAEL, Calif., June 28, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company resubmitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. In May 2021, the EMA granted the Company's request for accelerated assessment.  Accelerated assessment potentially reduces the time frame for the EMA Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) to review a MAA for an Adv
Jun 25, 2021 07:29 am ET
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
SAN RAFAEL, Calif., June 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for vosoritide, a once daily injection analog of C-type Natriuretic Peptide (CNP) to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.  Achondroplasia is the most common form of disproportionate short stature in humans.  A final approval decision, typically
Jun 15, 2021 08:30 am ET
BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference
SAN RAFAEL, Calif., June 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on June 16, 2021 at 3:30pm ET. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Mar 19, 2021 10:50 pm ET
BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).
Feb 25, 2021 03:05 pm ET
Feb 24, 2021 07:30 am ET
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
SAN RAFAEL, Calif., Feb. 24, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual conferences.  An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Feb 18, 2021 03:01 pm ET
BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the life sciences industry, Maykin Ho, Ph.D., to its Board of Directors.   
Jan 28, 2021 08:00 am ET
BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
SAN RAFAEL, Calif., Jan. 28, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the Company received the top score of 100 on the Human Rights Campaign Foundation's 2021 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality.  BioMarin joins the ranks of 767 major U.S. businesses that also earned top marks this year.
Jan 26, 2021 07:30 am ET
BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET
SAN RAFAEL, Calif., Jan. 26, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25, at 4:30 p.m. ET to discuss fourth quarter and full year 2020 financial results and provide a general business update.
Jan 15, 2021 10:50 pm ET
BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).
Jan 10, 2021 05:44 pm ET
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A.  This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants.  All participants in the study received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up. 
Jan 05, 2021 07:30 am ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
SAN RAFAEL, Calif., Jan. 5, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.  An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Dec 21, 2020 07:29 am ET
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
SAN RAFAEL, Calif., Dec. 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP), maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment.  These analyses are the result of the combination of data of the same patients enrolled in three consecutive trials.  In the first trial, a "run in" period consisted of longitudinal measurement of height in all
Dec 01, 2020 07:30 am ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
SAN RAFAEL, Calif., Dec. 1, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.  An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Nov 24, 2020 10:00 am ET
BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of...
Nov 24, 2020 09:13 am ET
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ:
Nov 23, 2020 09:50 pm ET
BIOMARIN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Ph
NEW ORLEANS, Nov. 23, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company's securities between February 28, 2020 and August 18, 2020, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.
Nov 23, 2020 12:00 pm ET
BMRN FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important Tuesday Deadline in Securities Class Action – BMRN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”), of the important November 24, 2020...
Nov 23, 2020 12:00 pm ET
DEADLINE ALERT for GTX, GTXMQ, BMRN, BTU, PT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 23, 2020 11:00 am ET
DEADLINE ALERT for WRTC, GLNG, GTX, GTXMQ, and BMRN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 22, 2020 10:50 pm ET
BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company’s securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Nov 20, 2020 10:50 pm ET
BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Ph
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company’s securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Nov 20, 2020 11:30 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals Inc. (BMRN)
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased BioMarin Pharmaceuticals Inc. (“BioMarin” or the “Company”) (NASDAQ:
Nov 20, 2020 08:00 am ET
BioMarin Pharmaceutical, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BioMarin Pharmaceutical, Inc. (NYSE: BMRN) investors that acquired shares between February 28, 2020 and August 18, 2020. Investors have until November...
Nov 19, 2020 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc....
Nov 19, 2020 11:07 am ET
BMRN ALERT NOV. 24 DEADLINE - Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the “Class Period”). The...
Nov 19, 2020 11:00 am ET
BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin securities between February 28, 2020 and August 18, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Nov 18, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMRN, BTU, CACC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: BioMarin Pharmaceutical Inc. (BMRN)Class Period:...
Nov 18, 2020 10:18 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Cont
NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the "Class Period"), of the important November 24, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for BioMarin investors under the federal securities laws.
Nov 18, 2020 11:00 am ET
GLNG & BMRN Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Upcoming Lead Plaintiff Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Nov 17, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMRN, BTU and RTX
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. BioMarin Pharmaceutical Inc. (BMRN) Class Period: February 28, 2020 and August 18, 2020Lead Plaintiff Motion...
Nov 17, 2020 11:45 am ET
DEADLINE ALERT for WRTC, GLNG, GTX, GTXMQ, and BMRN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 17, 2020 07:29 am ET
BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
SAN RAFAEL, Calif. and TORONTO, Nov. 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need.  Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones as a part of the collaboration.  BioMarin will receive an exclusive option to obtain Deep
Nov 16, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMRN, BTU, CACC, GOCO INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:      GoHealth, Inc. (GOCO) Class Period: Shares issued in connection with the July 2020 initial public...
Nov 16, 2020 11:07 am ET
IMMINENT SHAREHOLDER DEADLINE: BioMarin Pharmaceutical, Inc. Sued for Violations of the Federal Securities Laws; Investors Who Lost Money Should Contact Block & Leviton LLP Before November 24, 2020
On August 19, 2020, BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN) stunned the markets when it announced that the U.S. Food and Drug Administration had issued a Complete Response Letter (CRL) to the Company’s Biologics License Application (BLA) for...
Nov 16, 2020 11:00 am ET
DEADLINE ALERT for GTX, GTXMQ, BMRN, BTU, PT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.